Zealand Pharma A/S
CSE:ZEAL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
349.2
954
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Zealand Pharma A/S
Zealand Pharma A/S
Note Receivable
Zealand Pharma A/S
Note Receivable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Note Receivable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Note Receivable
kr23.9m
|
CAGR 3-Years
166%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Note Receivable
kr77m
|
CAGR 3-Years
33%
|
CAGR 5-Years
46%
|
CAGR 10-Years
27%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Note Receivable
€2.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Note Receivable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Note Receivable
kr4.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Note Receivable
kr4m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Note Receivable?
Note Receivable
23.9m
DKK
Based on the financial report for Sep 30, 2024, Zealand Pharma A/S's Note Receivable amounts to 23.9m DKK.
What is Zealand Pharma A/S's Note Receivable growth rate?
Note Receivable CAGR 3Y
166%
Over the last year, the Note Receivable growth was 1%. The average annual Note Receivable growth rates for Zealand Pharma A/S have been 166% over the past three years .
You don't have any saved screeners yet
